Patrick Corcoran, MD
Interventional Cardiology · Bloomfield, CTNPI 1144298415
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,500 of the $11,780 with a category attached, or 72.2%. 32 manufacturers reported payments, led by Abbott at 50.0% of the total. Reporting peaked in 2024 at $3,794 and has fallen 93.4% since, to $251 in 2025.
Across 385 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$692
- Pfizer$612
- Novartis$566
- AstraZeneca$411
- plus $2K from 26 others
What the payments were for
- Consulting fees$220%
- Travel & lodging$3,18827%
- Food & beverage$8,50072%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 64 | $5,890 |
| Johnson & Johnson | 85 | $1,246 |
| E.r. Squibb & Sons, L.L.C. | 43 | $692 |
| Pfizer | 42 | $612 |
| Novartis | 27 | $566 |
| AstraZeneca | 23 | $411 |
| Medtronic(2 entities) | 8 | $314 |
| Amgen | 11 | $213 |
| Philips North America LLC | 3 | $180 |
| Sanofi-aventis U.S. LLC | 8 | $176 |
| Amarin Pharma, Inc. | 10 | $170 |
| Boehringer Ingelheim | 6 | $144 |
| Terumo Medical Corporation | 1 | $128 |
| Boston Scientific | 4 | $112 |
| Merck | 5 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $85 |
| Shockwave Medical, Inc | 1 | $83 |
| Bard Peripheral Vascular, Inc. | 1 | $76 |
| Novo Nordisk | 4 | $76 |
| Bardy Diagnostics, Inc. | 9 | $75 |
| Kowa Pharmaceuticals America, Inc. | 5 | $70 |
| Inari Medical, Inc. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 2 | $47 |
| Akcea Therapeutics, Inc. | 2 | $45 |
| Sanofi | 2 | $33 |
| Baxter Healthcare | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Heartflow, Inc. | 1 | $17 |
| Preventice Services, LLC | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$3,597
- XIENCE SKYPOINT$603
- Xience Sierra Coronary Stent$134
- Optis Coronary Imaging System$130
- ELCA$129
- TR Band$128
- IN.PACT Admiral$120
- COROFLOW$117
- RESOLUTE ONYX$117
How this compares
$11,780 in reported general payments places this provider in the 70th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 199 | $250,603 |
| XareltoRivaroxaban | 59 | $91,680 |
| EntrestoSacubitril/Valsartan | 40 | $60,490 |
| Repatha SureclickEvolocumab | 12 | $17,526 |
| VascepaIcosapent Ethyl | 22 | $15,097 |
| Atorvastatin Calcium | 263 | $2,573 |
| ClopidogrelClopidogrel Bisulfate | 213 | $2,324 |
| Metoprolol Succinate | 155 | $1,892 |
| Ezetimibe | 65 | $1,469 |
| Metoprolol Tartrate | 181 | $1,063 |
| Amlodipine Besylate | 131 | $999 |
| Rosuvastatin Calcium | 48 | $938 |
| Nebivolol Hcl | 12 | $777 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $743 |
| Lisinopril | 118 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $612 | $250,603199 claims |
| Johnson & JohnsonXarelto | $1,246 | $91,68059 claims |
| NovartisEntresto | $566 | $60,49040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Bloomfield
- Jawad HaiderBloomfield$44K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
- Sarfaraz MemonHartford$30K
- Edward CarrerasStratford$30K
- Michael ChrissoherisNew Haven$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.